

FIG.1




FIG. 2




FIG. 2a




FIG. 2b

06112012_Sub fraction III #1138-1148 RT:18.92-19.08 AV:11 SB:240 15.60-18.52, 19.13-20.19 NL:3.80E7
T: +cAPCI corona Full ms [50.00-100.00]




FIG. 3




FIG. 3a




FIG. 3b

06112012_Sub Fraction IV #1053-1062 RT:17.75-18.05 AV:20 SB:19915.44-17.78, 18.42-19.45 NL:1.79E7
T: +cAPCI corona Full ms [50.00-100.00]




FIG. 3c

05112012_Sub Fraction IV #1109-1133 RT:18.66-18.89 AV:15 SB:241 15.98-18.53 18.94-20.36 NL:1.02E7

T: +cAPCI corona Full ms [50.00-100.00]




FIG. 4

G4112012_Scleropulin B enriched ethyl acetate subfractions

11/24/2012/ 11:39:00 AM


G4112012_SD_CFR_F04_1 #7-11 RT:0.53-0.20 AV:16 NL:1.2957
Tr: +6.6971 corrects full ms [50.00-1250.00]

FIG. 5

04112012_Scirpusin B enriched ethyl acetate subfractions

11/24/2012/ 11:41:43 AM

04112012_RD_CVR_PR_4_02 #3-13 RT:0.04-0.22 AV:10 NL:9.04E5

T: +cAPCI corona Full ms [50.00-1250.00]




FIG.6




FIG.6a




FIG. 6b





FIG. 7

SUBJECT 001 – PRE TREATMENT



SUBJECT 001 – POST TREATMENT





FIG. 8a

SUBJECT 016 – PRE TREATMENT



SUBJECT 016 – POST TREATMENT




FIG. 8b

SUBJECT 024 – PRE TREATMENT



SUBJECT 024 – POST TREATMENT



FIG. 8c

SUBJECT 030 – PRE TREATMENT



SUBJECT 030 – POST TREATMENT




FIG. 9a




FIG. 9b




FIG. 9c




FIG. 9d




Fig. 9e

